These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 358212)

  • 1. Circulatory and anti-platelet effects of intravenous prostacyclin in healthy men.
    Szczeklik A; Gryglewski RJ; Nizankowski R; Musiał J; Pietoń R; Mruk J
    Pharmacol Res Commun; 1978 Jun; 10(6):545-56. PubMed ID: 358212
    [No Abstract]   [Full Text] [Related]  

  • 2. Evaluation of prostaglandin and prostacyclin antagonism at platelet receptors by aggregometry.
    Eggerman TL; Harker LA; Andersen NH; Wilson CH
    Adv Prostaglandin Thromboxane Res; 1980; 6():389-93. PubMed ID: 6247888
    [No Abstract]   [Full Text] [Related]  

  • 3. Cardiovascular and platelet effects in man of BW 245C, a stable mimic of epoprostenol (PGI2).
    Orchard MA; Ritter JM; Shepherd GL; Lewis PJ
    Br J Clin Pharmacol; 1983 May; 15(5):509-11. PubMed ID: 6344895
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of prostacyclin on platelet-activating factor induced rabbit and platelet aggregation.
    Bussolino F; Camussi G
    Prostaglandins; 1980 Nov; 20(5):781-91. PubMed ID: 6258196
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anti-platelet action of intravenous infusion of prostacyclin in man.
    Gryglewski RJ; Szczeklik A; Nizankowski R
    Thromb Res; 1978 Aug; 13(2):153-63. PubMed ID: 358486
    [No Abstract]   [Full Text] [Related]  

  • 6. Stimulated platelet aggregation, thromboxane B2 formation and platelet sensitivity to prostacyclin - a critical evaluation.
    Siess W; Roth P; Weber PC
    Thromb Haemost; 1981 Jun; 45(3):204-7. PubMed ID: 7025338
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Is prostacyclin a physiologically important circulating anti-platelet agent?
    Steer ML; MacIntyre DE; Levine L; Salzman EW
    Nature; 1980 Jan; 283(5743):194-5. PubMed ID: 6243178
    [No Abstract]   [Full Text] [Related]  

  • 8. The generation of TXA2 in human platelet rich plasma and its inhibition by nictindole and prostacyclin.
    Grodzińska L; Marcinkiewicz E
    Pharmacol Res Commun; 1979 Feb; 11(2):133-46. PubMed ID: 375247
    [No Abstract]   [Full Text] [Related]  

  • 9. Heparin opposes prostanoid and non-prostanoid platelet inhibitors by direct enhancement of aggregation.
    MacIntyre DE; Handin RI; Rosenberg R; Salzman EW
    Thromb Res; 1981 Apr 1-15; 22(1-2):167-75. PubMed ID: 6270842
    [No Abstract]   [Full Text] [Related]  

  • 10. Epoprostenol (prostacyclin) decreases platelet deposition on vascular prosthetic grafts.
    Sinzinger H; O'Grady J; Cromwell M; Hofer R
    Lancet; 1983 Jun; 1(8336):1275-6. PubMed ID: 6134062
    [No Abstract]   [Full Text] [Related]  

  • 11. Platelet sensitivity to adenosine diphosphate and to prostacyclin in diabetic patients.
    Onodera H; Hirata T; Sugawara H; Sugai K; Yoda B; Toyota T; Goto Y
    Tohoku J Exp Med; 1982 Aug; 137(4):423-8. PubMed ID: 6750843
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Role of cyclic AMP in the inhibition of human platelet aggregation by quercetin, a flavonoid that potentiates the effect of prostacyclin.
    Beretz A; Stierle A; Anton R; Cazenave JP
    Biochem Pharmacol; 1982 Nov; 31(22):3597-600. PubMed ID: 6295405
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prostacyclin inhibits mobilisation of fibrinogen-binding sites on human ADP- and thrombin-treated platelets.
    Hawiger J; Parkinson S; Timmons S
    Nature; 1980 Jan; 283(5743):195-7. PubMed ID: 6985716
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Platelet sensitivity to prostacyclin in pregnancy and uterine cancer.
    Briel RC; Lippert TH
    Eur J Obstet Gynecol Reprod Biol; 1981 Jun; 12(1):19-23. PubMed ID: 7018952
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Platelets from diabetic subjects show diminished sensitivity to prostacyclin.
    Betteridge DJ; El Tahir KE; Reckless JP; Williams KI
    Eur J Clin Invest; 1982 Oct; 12(5):395-8. PubMed ID: 6816610
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of prostacyclin infusion in uremic patients: hematologic and hemodynamic responses.
    Zusman RM; Crow JW; Cato AE; Tolkoff-Rubin N
    Clin Pharmacol Ther; 1981 Aug; 30(2):251-7. PubMed ID: 7018791
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Platelet sensitivity to prostacyclin in diabetes mellitus.
    Pillay PK; Pillay U; Balasubramaniam P; Lee KO
    Ann Acad Med Singap; 1985 Apr; 14(2):229-31. PubMed ID: 3898978
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibition of platelet aggregation and reversal of vasopressin-induced ECG changes by a carboprostacyclin analogue, ONO 41483, in primates.
    Adaikan PG; Kottegoda SR; Lau LC; Tai MY; Karim SM
    Prostaglandins Leukot Med; 1982 Sep; 9(3):307-20. PubMed ID: 6752959
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of sulphated polysaccharides on prostacyclin (prostaglandin I2)-induced inhibition of platelet aggregation [proceedings].
    Kindness G; Williamson FB; Long WF
    Biochem Soc Trans; 1980 Jun; 8(3):377-9. PubMed ID: 6995209
    [No Abstract]   [Full Text] [Related]  

  • 20. Prostacyclin (PGI2) and the effect of phosphodiesterase inhibitors on platelet aggregation.
    Jørgensen KA; Dyerberg J; Stoffersen E
    Pharmacol Res Commun; 1979 Jul; 11(7):605-15. PubMed ID: 388470
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.